Filters:
805 Projects | 558 Researchers | $380,393,824 Invested
2025
Vesper Bio ApS
Mads Fuglsang Kjølby
Open-label multiple dosing study in asymptomatic GRN-Frontotemporal dementia patients to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VES001.
2025
The University of Texas Southwestern Medical Center at Dallas
Marc Diamond, MD
AAV-mediated clearance of tau aggregates in vivo
2025
University of Illinois at Chicago
Steven Ackerman, PhD
Development of novel CCR3 chemokine receptor peptide and small molecule functionally selective biased antagonists to treat neuroinflammation in Alzheimer’s disease.
2025
Monash University
Joanne Ryan, PhD
Leveraging a large scale randomized clinical trial to determine whether statins can prevent Alzheimer’s Disease neuropathology and dementia
2025
Beth Israel Deaconess Medical Center
Chenxi Qiu, PhD
A new therapeutic antibody for Frontotemporal Dementia
2025
University of Pennsylvania
James Shorter, PhD
Defining oligonucleotide therapeutics that reverse FUS proteinopathy
2025
Emory University
Thomas Kukar, PhD
Development of a granulin biologic to treat progranulin deficient FTD.
2025
Stanford University
Giuseppe Barisano, MD, PhD
Assessing the diagnostic and prognostic value of perivascular spaces imaging in cognitive impairment and dementia through a novel fully-automated robust algorithm
2025
Foundation for the National Institutes of Health, Inc.
Tatiana Lagos , MBA
Alzheimer’s Disease Blood-Based Biosignature for Predicting Clinical Progression
2025
Circular Genomics Inc
Nikolaos Mellios, MD, PhD
Alzheimer’s disease specificity and sensitivity analyses of circRNA blood biomarkers